Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells

Blood

Volumn 103, Issue 5, 2004, Pages 1846-1854

  Mone, Andrew P ^b   Huang, Peng ^b   Pelicano, Helene ^b   Cheney, Carolyn M ^b   Green, Jennifer M ^b   Tso, J Yun ^b   Johnson, Amy J ^b   Jefferson, Sara ^b   Lin, Thomas S ^b   Byrd, John C ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; APOLIZUMAB; HLA ANTIBODY; PROTEIN KINASE B; PROTEIN KINASE SYK; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CASE REPORT; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MITOCHONDRIAL RESPIRATION; PHOSPHORYLATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 10744232852     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-08-2836     Document Type: Article

References (79)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000;50:7-33.
2. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219-234.
3. Binet JL, Lepoprier M, Dighiero G, et al. A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer. 1977;40:855-864.
4. Byrd JC, Rai KR, Sausville EA, Grever MR. Old and new therapies in chronic lymphocytic leukemia: now is the time for a reassessment of therapeutic goals. Semin Oncol. 1998;25:65-74.
5. Kipps TJ. Chronic lymphocytic leukemia. Curr Opin Hematol. 2000;7:223-234.
6. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343:1750-1757.
7. Johnson S, Smith AG, Loffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet. 1996;347:1432-1438.
8. Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood. 2001;98:2319-2325.
9. Flinn IW, Byrd JC, Morrison C, et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood. 2000;96:71-75.
10. Flinn IW, Jemiai Y, Bennett JM, et al. Fludarabine and cyclophosphamide achieves high complete response rate in patients with previously untreated chronic lymphocytic leukemia: ECOG 1997 [abstract]. Blood. 1997;98:633a.
11. O'Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001;19:1414-1420.
12. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
13. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1998;9:995-1001.
14. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999;94:2217-2224.
15. Nguyen DT, Amess JA, Doughty H, Hendry L, Diamond LW. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur J Haematol. 1999;62:76-82.
16. Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000;18:317-324.
17. Ladetto M, Bergui L, Ricca I, Campana S, Pileri A, Tarella C. Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients. Med Oncol. 2000;17:203-210.
18. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001;19:2165-2170.
19. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 2001;19:2153-2164.
20. Byrd JC, Peterson BL, Park K, et al. Concurrent rituximab and fludarabine has a higher complete response rate than sequential treatment in untreated chronic lymphocytic leukemia patients: results from CALGB 9712 [abstract]. Blood. 2001;98:772a.
21. Osterborg A, Fassas AS, Anagnostopoulos A, Dyer MJ, Catovsky D, Mellstedt H. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol. 1996;93:151-153.
22. Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol. 1997;15:1567-1574.
23. Bowen AL, Zomas A, Emmett E, Matutes E, Dyer MJ, Catovsky D. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br J Haematol. 1997;96:617-619.
24. Rawstron AC, Davies FE, Evans P. Campath-1H therapy for patients with refractory chronic lymphocytic leukemia [abstract]. Blood. 1997;88:529a.
25. Keating MJ, Byrd JC, Rai KR, et al. Campath-1H collaborative study group. Multicenter study of Campath-1H in patients with chronic lymphocytic leukemia refractory to fludarabine [abstract]. Blood. 1999;94:705a.
26. Byrd JC, Kitada S, Flinn IW, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002;99:1038-1043.
27. Bannerji R, Kitada S, Flinn IW, et al. Campath-1H antibody induces transmembrane signaling in vitro and in vivo in patients with chronic lymphocytic leukemia and promotes tumor clearance in part through caspase mediated apoptosis [abstract]. Blood. 2001;98:808a.
28. Newell MK, VanderWall J, Beard KS, Freed JH. Ligation of major histocompatibility complex class II molecules mediates apoptotic cell death in resting B lymphocytes. Proc Natl Acad Sci U S A. 1993;90:10459-10463.
29. Higaki Y, Hata D, Kanazashi S, et al. Mechanisms involved in the inhibition of growth of a human B lymphoma cell line, B104, by anti-MHC class II antibodies. Immunol Cell Biol. 1994;72:205-214.
30. Truman JP, Ericson ML, Choqueux-Seebold CJ, Charron DJ, Mooney NA. Lymphocyte programmed cell death is mediated via HLA class II DR. Int Immunol. 1994;6:887-896.
31. Truman JP, Choqueux C, Tschopp J, et al. HLA class II-mediated death is induced via Fas/Fas ligand interactions in human splenic B lymphocytes. Blood. 1997;89:1996-2007.
32. Drenou B, Blancheteau V, Burgess DH, Fauchet R, Charron DJ, Mooney NA. A caspase-independent pathway of MHC class II antigen-mediated apoptosis of human B lymphocytes. J Immunol. 1999;63:4115-4124.
33. Kostelny SA, Link BK, Tso JY, et al. Humanization and characterization of the anti-HLA-DR antibody 1D10. Int J Cancer. 2001;93:556-565.
34. Nagy ZA, Hubner B, Lohning C, et al. Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. Nat Med. 2002;8:801-807.
35. Blancheteau V, Charron D, Mooney N. HLA class II signals sensitize B lymphocytes to apoptosis via Fas/CD95 by increasing FADD recruitment to activated Fas and activation of caspases. Hum Immunol. 2002;63:375-383.
36. Green J, Tso JY. Rapid redistribution of HLA-DR to membrane rafts induced by humanized mAb 1D10 results in apoptosis on B-cell lymphomas [abstract]. Blood. 2000;96:133a.
37. Gingrich RD, Dahle CE, Hoskins KF, Senneff MJ. Identification and characterization of a new surface membrane antigen found predominantly on malignant B lymphocytes. Blood. 1990;75:2375-2387.
38. Link BK, Wang H, Byrd J, Leonard J, et al. Phase I trial of humanized 1D10 (Hu1D10) monoclonal antibody targeting class II molecules in patients with relapsed lymphoma [abstract]. Proc Am Soc Clin Oncol. 2000;19:24a.
39. King MP, Attardi G. Isolation of human cell lines lacking mitochonddal DNA. Methods Enzymol. 1996;264:304-313.
40. Chandel NS, Mattepe E, Goldwasser E, Mathieu CE, Simon MC, Schumacker PT. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci U S A. 1998;95:11715-11720.
41. Pelicano H, Feng L, Zhou Y, et al. Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by an ROS-mediated mechanism. J Biol Chem. 2003;278:37832-37839.
42. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997.
43. Lin T, Stock W, Lucas M, et al. A phase I dose escalation study of apolizumab (Hu1D10) using a stepped up dosing schedule in patients with chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL) [abstract]. Blood. 2002;100:802a.
44. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood. 1994;84:1415-1420.
45. Johnson LV, Walsh ML, Chen LB. Localization of mitochondria in living cells with rhodamine 123. Proc Natl Acad Sci U S A. 1980;77:990-994.
46. Zamzami N, Marchetti P, Castedo M, et al. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J Exp Med. 1995;181:1661-1672.
47. McGinty A, Chang YW, Sorokin A, Bokemeyer D, Dunn MJ. Cyclooxygenase-2 expression inhibits trophic withdrawal apoptosis in nerve growth factor-differentiated PC12 cells. J Biol Chem. 2000;275:12095-12101.
48. Bellosillo B, Villamor N, Lopez-Guillermo A, et al. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood. 2001;98:2771-2777.
49. Byrd JC, Shinn C, Waselenko JK, et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood. 1998;92:3804-3816.
50. Dillon SR, Mancini M, Rosen A, Schlissel MS. Annexin V binds to viable B cells and colocalizes with a marker of lipid rafts upon B cell receptor activation. J Immunol. 2000;164:1322-1332.
51. Genini D, Adachi S, Chao Q, et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNAand by directly affecting the mitochondria. Blood. 2000;96:3537-3543.
52. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol. 1999;17:2941-2953.
53. Mateo V, Brown EJ, Biron G, et al. Mechanisms of CD47-induced caspase-independent cell death in normal and leukemic cells: link between phosphatidylserine exposure and cytoskeleton organization. Blood. 2002;100:2882-2890.
54. Fernandez EM, O'Toole PJ, Morrison IE, Cherry RJ, Fernandez N. Interaction of HLA-DR with actin microfilaments. Hum Immunol. 2003;64:327-337.
55. Huby RD, Dearman RJ, Kimber I. Intracellular phosphotyrosine induction by major histocompatibility complex class II requires co-aggregation with membrane rafts. J Biol Chem. 1999;274:22591-22596.
56. Bouillon M, El Fakhry Y, Girouard J, Khalil H, Thibodeau J, Mourad W. Lipid raft-dependent and -independent signaling through HLA-DR molecules. J Biol Chem. 2003;278:7099-7107.
57. Furukawa K, Tengler R, Nakamura M, et al. B lymphoblasts show oxidase activity in response to cross-linking of surface IgM and HLA-DR. Scand J Immunol. 1992;35:561-567.
58. Becker LB, vanden Hoek TL, Shao ZH, Li CQ, Schumacker PT. Generation of superoxide in cardiomyocytes during ischemia before reperfusion. Am J Physiol. 1999;277:H2240-2246.
59. Maly FE, Nakamura M, Gauchat JF, et al. Superoxide-dependent nitroblue tetrazolium reduction and expression of cytochrome b-245 components by human tonsillar B lymphocytes and B cell lines. J Immunol. 1989;142:1260-1267.
60. Tabata H, Matsuoka T, Endo F, Nishimura Y, Matsushita S. Ligation of HLA-DR molecules on B cells induces enhanced expression of IgM heavy chain genes in association with Syk activation. J Biol Chem. 2000;275:34998-35005.
61. Orie NN, Zidek W, Tepel M. Tyrosine and calcium/calmodulin kinases are common signaling components in the generation of reactive oxygen species in human lymphocytes. Life Sci. 1999;65:2135-2142.
62. 2+ signals. J Biol Chem. 1993;268:16688-16692.
63. Ding J, Takano T, Gao S, et al. Syk is required for the activation of Akt survival pathway in B cells exposed to oxidative stress. J Biol Chem. 2000;275:30873-30877.
64. Hossain K, Akhand AA, Kawamoto Y, et al. Caspase activation is accelerated by the inhibition of arsenite-induced, membrane rafts-dependent Akt activation. Free Radic Biol Med. 2003;34:598-606.
65. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91:231-241.
66. Cardone MH, Roy N, Stennicke HR, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science. 1998;282:1318-1321.
67. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem. 1994;269:5241-5248.
68. Thakkar K, Geahlen RL, Cushman M. Synthesis and protein-tyrosine kinase inhibitory activity of polyhydroxylated stilbene analogues of piceatannol. J Med Chem. 1993;36:2950-2955.
69. Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2002;100:4609-4614.
70. Pogue SL, Kurosaki T, Bolen J, Herbst R. B cell antigen receptor-induced activation of Akt promotes B cell survival and is dependent on Syk kinase. J Immunol. 2000;165:1300-1306.
71. Wickremasinghe RG, Ganeshaguru K, Jones DT, et al. Autologous plasma activates Akt/protein kinase B and enhances basal survival and resistance to DNA damage-induced apoptosis in B-chronic lymphocytic leukaemia cells. Br J Haematol. 2001;114:608-615.
72. Barragan M, Bellosillo B, Campas C, Colomer D, Pons G, Gil J. Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells. Blood. 2002;99:2969-2976.
73. Jones DT, Ganeshaguru K, Anderson RJ, et al. Albumin activates the AKT signaling pathway and protects B-chronic lymphocytic leukemia cells from chlorambucil- and radiation-induced apoptosis. Blood. 2003;101:3174-3180.
74. Takano T, Sada K, Yamamura H. Role of protein-tyrosine kinase syk in oxidative stress signaling in B cells. Antioxid Redox Signal. 2002;4:533-541.
75. Hossain K, Akhand AA, Kato M, et al. Arsenite induces apoptosis of murine T lymphocytes through mambrane raft-linked signaling for activation of c-Jun amino-terminal kinase. J Immunol. 2000;165:4290-4297.
76. Nakashima I, Kato M, Akhand AA, et al. Redox-linked signal transduction pathways for protein tyrosine kinase activation. Antioxid Redox Signal. 2002;4:517-531.
77. Byrd JC, Shinn C, Willis CR, et al. UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism. Exp Hematol. 2001;29:703-708.
78. Sato S, Fujita N, Tsuruo T. Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene. 2002;21:1727-1738.
79. Zhu J, Song X, Lin HP, et al. Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. J Natl Cancer Inst. 2002;94:1745-1757.